Background The changes in body composition that occur in response to therapy for localized pancreatic ductal adenocarcinoma (PDAC) and during the early survivorship period, as well as their clinical significance, are poorly understood. Methods One hundred twenty-seven consecutive patients with PDAC who received preoperative therapy followed by pancreatoduodenectomy (PD) at a single institution between 2009 and 2012 were longitudinally evaluated. Changes in skeletal muscle (SKM), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were measured on serial computed tomography images obtained upon presentation, prior to pancreatectomy, and approximately 3 and 12 months after surgery. Results Prior to therapy, patients' mean baseline BMI was 26.5 ± 4.7 kg/m 2 and 63.0% met radiographic criteria for sarcopenia. During a mean 5.4 ± 2.3 months of preoperative therapy, minimal changes in SKM (− 0.5 ± 7.8%, p > 0.05), VAT (− 1.8 ± 62.6%, p < 0.001), and SAT (− 4.8 ± 27.7%, p < 0.001) were observed. In contrast, clinically significant changes were observed on postoperative CT compared to baseline anthropometry: SKM − 4.1 ± 10.7%, VAT − 38.7 ± 30.2%, and SAT − 24.1 ± 22.6% (all p < 0.001) and these changes persisted at one year following PD. While anthropometric changes during preoperative therapy were not independently associated with survival, SKM gain between the postoperative period and one-year follow-up was associated with improved overall survival (OR 0.50, 95% CI 0.29-0.87). Conclusions In contrast to the minor changes that occur during preoperative therapy for PDAC, significant losses in key anthropometric parameters tend to occur over the first year following PD. Ongoing SKM loss in the postoperative period may represent an early marker for worse outcomes.
Introduction
Patients with pancreatic ductal adenocarcinoma (PDAC) commonly experience anthropometric changes in association with their cancer. 1 The involuntary loss of skeletal muscle is a poor prognostic factor among patients with lung, gastrointestinal, and hepatopancreatobiliary cancers, 2, 3 including advanced PDAC. 4 Among patients with newly diagnosed PDAC, the depletion of skeletal muscle has been associated with shorter survival following pancreatectomy. 3, 5, 6 Although the etiology of this observation is probably multifactorial, it may in part reflect relative differences in the physiologic reserve between patients who present with early and advanced disease or differences in patients' ability to tolerate therapy. 7 On the other hand, treatments for PDAC may themselves contribute to nutritional and physiologic depletion. 4 We have previously shown that depletion of skeletal muscle, visceral adipose tissue, and subcutaneous adipose tissue occurs concurrent with preoperative therapy but that these changes do not preclude subsequent pancreatectomy. 8 Other studies have reported that clinically significant anthropometric changes occur during neoadjuvant therapy for various malignancies. [9] [10] [11] However, the anthropometric and nutritional changes that occur following curative therapy for localized PDAC and throughout the survivorship period have not previously been investigated. Such changes might have a prognostic value and/or reflect physiologic disturbances that might be targeted to optimize treatment outcomes.
The purpose of this study was to quantify and characterize the anthropometric and nutritional changes that occur in patients with localized PDAC over the course of therapy and the first postoperative year and to document their associations, if any, with survival. We hypothesized that clinically significant derangements of key anthropometric indices would occur during therapy.
Materials and Methods
The University of Texas MD Anderson Cancer Center's (MDACC) institutional review board approved this retrospective study. Patients were identified from a prospectively maintained institutional pancreatic tumor database. 12 Consecutive patients with PDAC who completed preoperative chemotherapy and/or chemoradiation and underwent pancreatoduodenectomy (PD) between January 2009 and December 2012 were included.
Staging
Prior to the initiation of preoperative therapy, patients underwent comprehensive clinical and radiographic staging that included cross-sectional computed tomography (CT) imaging of the abdomen and pelvis, a chest x-ray or CT scan, a physical examination, and full laboratory studies, including serum CA 19-9 level. Tumors were anatomically staged as potentially resectable, borderline resectable, or locally advanced based on previously published MD Anderson criteria. 13 
Preoperative Therapy
Preoperative therapy was administered, either on or off protocol, according to the recommendations of each patient's multidisciplinary care team, and it was delivered either at MDACC or at the referring facility in close collaboration with MD Anderson physicians. Several chemotherapy regimens were utilized during the study period.
14 External-beam radiation therapy was generally delivered to a total of 50.4 Gy over 6 weeks (standard fractionated 1.8 Gy, 28 fractions) or to a total of 30 Gy over 2 weeks (hypofractionated 3 Gy, 10 fractions) with concurrent 5-fluorouracil (FU), capecitabine, or gemcitabine. 15 
Pancreatoduodenectomy
Within 4-8 weeks following completion of all intended preoperative therapy, patients underwent a comprehensive restaging evaluation. Patients with a performance status sufficient for major abdominal surgery and who had no radiographic or intraoperative findings of disease progression were selected for pancreatectomy. 16 PD was performed at MDACC using a standardized technique. 17 Postoperative Therapy and Follow-up Following pancreatectomy, postoperative therapy was administered selectively based on individual patient and pathology characteristics and physician preference. Patients were typically evaluated initially every 3-4 months, later extended to every 6 months, with cross-sectional imaging, physical examination, and CA 19-9 analysis according to a standardized surveillance protocol. 18 
Anthropometric Analysis
The cross-sectional areas of skeletal muscle (SKM), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were assessed at the L3 vertebral body midpoint on serial CT images ( Fig. 1 ) using sliceOmatic v5.0 software (TomoVision, Magog, Canada). Cross-sectional areas were standardized to the square of the patient's height in meters. Gender-specific thresholds defining radiographic evidence of sarcopenia were established as ≤ 38.9 cm for men. 19 Body mass index (BMI), calculated by dividing the patient's weight in kilograms by height in meters squared, and serum albumin were also measured at corresponding time points.
Statistical Analysis
Anthropometric and nutritional parameters were measured upon presentation, prior to PD, and approximately 3 and 12 months after surgery. Differences compared to baseline were first assessed using paired t tests. These comparisons only test for differences in the setting of complete data, which were not available for all patients. In order to control for missing data, changes over time for each anthropometric and nutritional parameter were also analyzed utilizing a multilevel mixed-effect linear regression model, which takes into account correlations between measurements and fixed effects. Beta coefficients (Β) and 95% confidence intervals (CIs) were calculated.
Next, univariate Cox proportional hazards regression models were created to evaluate the association between clinicopathologic and anthropometric factors and overall survival, which was calculated from the date of tissue diagnosis to the date of death. Baseline values as well as changes in anthropometrics over time, per 10 units cm 2 /m 2 , were analyzed for their potential association with survival. Hazard ratios (HR) and 95% CIs were calculated. Statistical significance was set at a two-tailed p value < 0.05. All statistical analyses were performed using Stata/SE version 14.1 statistical software (StataCorp LLC, College Station, TX).
Results
The clinicopathologic profile of 127 consecutive patients with PDAC who received chemotherapy and/or chemoradiation prior to PD is reported in Table 1 . Upon presentation, patients' mean age was 64.6 ± 8.9 years, their mean BMI was 26.5 ± 4.7 kg/m 2 , and 80 (63.0%) met established radiographic criteria for evidence of sarcopenia. Prior to PD, 12 (9.4%) patients received chemotherapy alone, 44 (34.6%) received chemoradiation alone, and 71 (55.9%) received both, over a mean duration of 5.4 ± 2.3 months. The surgical specimens of 122 (96.1%) patients had negative (R0) margins; 62 (48.8%) had negative lymph nodes. Following surgery, 64 (50.4%) patients received postoperative systemic chemotherapy. Table 2 reports changes in anthropometric and key laboratory parameters as measured prior to the administration of preoperative therapy, prior to PD, and approximately 3 and 12 months following surgery. Among all 127 patients, CT scans were available for 126 (99.2%) at baseline, 124 (97.6%) preoperative, 121 (95.3%) postoperative, and 90 (74.4%) at one year. During a mean 5.4 ± 2.3 months of preoperative therapy, minimal changes in SKM (− 0.5 ± 7.8%, p > 0.05), VAT (− 1.8 ± 62.6%, p < 0.001), and SAT (− 4.8 ± 27.7%, p < 0.001) were observed. In contrast, clinically significant changes were observed on postoperative CT compared to baseline anthropometry: SKM − 4.1 ± 10.7%, VAT − 38.7 ± 30.2%, and SAT − 24.1 ± 22.6% (all p<0.001) and these changes persisted at one year following PD. Similar results were found when we accounted for all data while using mixed models ( Table 3) .
The median overall survival duration of patients was 32.8 months (95% CI 27.7-37.9 months). On univariate Cox proportional hazards regression, tumor size, differentiation, lymph node status, histopathologic treatment effect, 20 lymph node ratio, lymphovascular invasion, and perineural invasion were associated with overall survival (Table 4) . However, baseline body composition characteristics as well as anthropometric changes that occurred during preoperative therapy were not associated with overall survival. On the other hand, relative increases in SKM (HR 0.50, 95% CI 0.29-0.87) and albumin (HR 0.57, 95% CI 0.36-0.89) between the postoperative period and 12-month follow-up were associated with improved overall survival. 
Discussion
We conducted this study to investigate the hypothesis that clinically significant changes in body composition may occur in patients during and immediately following treatment for localized PDAC. By analyzing standard CT images that were serially and routinely performed throughout the course of therapy and the first postoperative year, we found that the skeletal muscle and body mass of patients selected for pancreatectomy were maintained during the administration of preoperative chemotherapy and/or chemoradiation. However, progressive depletion of body mass, fat, and muscle occurred over the first postoperative year. Relative increases in skeletal muscle and serum albumin between the perioperative period and 12-month follow-up were associated with improved overall survival.
Although minor decreases in visceral and subcutaneous adiposity were observed during preoperative therapy, on average patients were able to maintain their skeletal muscle and body mass indices. This is important as preoperative sarcopenia has been shown to be an important risk factor for postoperative complications following pancreatectomy [21] [22] [23] [24] [25] [26] [27] [28] and that some studies have demonstrated either a decrease in SKM 8 or muscle attenuation 11 during preoperative therapy for PDAC. In fact, we previously showed that minor changes in SKM, VAT, and SAT occur during preoperative therapy for PDAC but that these changes did not preclude subsequent pancreatectomy nor were they associated with survival. 8 However, the current study may be somewhat more generalizable in its patient population (as the previous study was of a small cohort of clinical trial patients with, in general, excellent performance status) and also differed in that only patients who underwent surgery were included. Nevertheless, a greater understanding of the etiology and magnitude of changes in body composition that occur in association with preoperative therapy, and the extent to which they are reversible and/or preventable, is clearly needed. Although few prior studies have characterized changes in either nutritional indices or body composition following pancreatectomy, [29] [30] [31] [32] the results of those studies, together with the data described herein, clearly document that adverse physiologic changes do occur and, more importantly, that they persist long after surgery. In this study, patients experienced a significant loss of weight and serum albumin, and a progressive depletion of both muscle and fat, in the year following PD. In a study of physiologic changes that occurred in 27 patients during the first 6 months following PD, Aslani et al. found that both fat mass and total body protein declined in the early postoperative period but by 6 months, measures of protein (but not fat mass) returned to preoperative levels. 29 In a more recent study, Hashimoto et al. found that 93 patients who underwent pancreatectomy had lost 8.4% of body weight at 2 months after surgery and 9% of body weight by 4 months. 33 Given that patients who lose significant weight are at risk for receiving lower doses of chemotherapy, a shorter duration of chemotherapy, and greater dose-limiting toxicities, 34 heightened attention to postoperative nutrition and optimizing patient performance status and function seems warranted.
Although changes during preoperative therapy and immediately following surgery were not associated with the overall survival of patients in this study, the inability to restore skeletal muscle mass during the follow-up period was. Other studies have found significant decreases in body weight following gastrointestinal cancer surgery and that greater losses were predictive of early recurrence and poor survival. [35] [36] [37] Whether loss of skeletal muscle is a direct cause of increased mortality (and therefore potentially modifiable) or, more likely, an early indicator of disease recurrence is unknown. Regardless, this anthropometric parameter is easily measured and may confer clinically important information to patients and providers. In the future, combining clinically relevant anthropometric information with other validated assessment tools may permit accurate prediction of short-term outcomes. 24, 25 That adverse anthropometric changes occur during the course of therapy for PDAC suggests that opportunities to enhance nutritional and physiologic support exist throughout the treatment and survivorship periods. In the preoperative setting, we and others have implemented exercise and nutrition programs designed to improve patients' physiologic status prior to 38 or counter the cytotoxic effects of chemotherapy and radiation on fat and muscle mass. 39, 40 Despite this interest, there is a scarcity of published literature on the topic of prehabilitation among patients with localized PDAC treated with preoperative therapy. 41 Given the findings of the current study, efforts at maintaining muscle mass in the ongoing survivorship period are also clearly justified. Such efforts might include exercise programs, extended rehabilitation, nutritional supplementation, regular follow-up with trained nutritional professionals, or drugs targeting inflammation and cachexia. [42] [43] [44] A major strength of the current study is the longitudinal assessment of serial anthropometric measurements in a relatively large cohort of patients with PDAC throughout their course of therapy over a full postoperative year. Nevertheless, several limitations should be acknowledged. First, although inexpensive, comprehensive, and reproducible, the methods we utilized in this study for anthropometric measurement are only one of several possible approaches; previous studies have used other measures that include total psoas volume, 23 total psoas area, 27 psoas muscle mass index, 45 intramuscular adipose tissue content, 45 Hounsfield unit average calculation, 6 total psoas index, 6 psoas thickness, 46 and the psoas-vertebral index. 47 And automated image processing software and more sophisticated techniques, such as analytic morphomics, now allow investigators to take advantage of whole-body anthropometric data instead of data generated at a single vertebral level. 24, 48 In addition, we used validated Hounsfield unit thresholds for tissue labeling; to the best of our knowledge, this methodology has not been validated in the postoperative setting. However, measurements were made at the level of the L3 vertebra, a level at which few anatomic alterations occur secondary to PD, and none of the 3 month postoperative scans had evidence of significant complications (e.g., fluid collections). Second, our study only included patients who completed all intended aspects of therapy-namely, preoperative chemotherapy and/or radiation and surgical resection. Third, most of the patients in this study received gemcitabine-or 5-FU-based preoperative regimens. Whether the results here are generalizable to patients with PDAC who received different sequencing strategies or regimens (e.g., FOLFIRINOX) is unclear. It is possible that more aggressive regimens could result in even more pronounced anthropometric changes than were seen in the current study. Finally, we acknowledge that the loss of skeletal muscle mass and function are both important components of sarcopenia [49] [50] [51] ; however, the primary purpose of our study was to characterize longitudinal changes in body composition as they occur within the first year of pancreatectomy and only characterized patients on the basis of pre-specified, radiographic norms of sarcopenia to provide additional context.
Conclusion
In summary, we performed a longitudinal assessment of anthropometric changes occurring throughout the course of therapy and follow-up for patients with PDAC. We found that in contrast to the relatively minor changes in body composition that occur during preoperative therapy, significant losses in key anthropometric parameters tend to occur over the first year following PD, and ongoing skeletal muscle loss Authors' Contributions All authors made substantial contributions to the -conception or design of the work; or the acquisition, analysis, or interpretation of data for the work -drafting the work or revising it critically for important intellectual content -final approval of the version to be published -agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
